Literature DB >> 12591748

Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes.

Teruhiko Ito1, Michihiro Yoshimura, Shota Nakamura, Masafumi Nakayama, Yukio Shimasaki, Eisaku Harada, Yuji Mizuno, Megumi Yamamuro, Masaki Harada, Yoshihiko Saito, Kazuwa Nakao, Hiroki Kurihara, Hirofumi Yasue, Hisao Ogawa.   

Abstract

BACKGROUND: Although previously thought to be synthesized solely in adrenal cortex, we have recently showed that aldosterone is also produced in and the expression of CYP11B2 mRNA was induced in the failing or hypertensive human ventricle. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones with wide biological effects, including inhibition of renin and aldosterone production. We hypothesized that natriuretic peptides reduce the expression of CYP11B2 mRNA in the heart. METHODS AND
RESULTS: To test this hypothesis, we examined whether endogenous or exogenous natriuretic peptides reduce the expression of CYP11B2 mRNA using real-time reverse transcription-polymerase chain reaction. By using HS 142-1, a functional guanylyl cyclase-A type receptor antagonist, we showed that angiotensin II (AngII) pretreated with HS 142-1 increased CYP11B2 mRNA expression (1.62+/-0.12-fold, HS 142-1+AngII 10(-7) mol/L versus AngII 10(-7) mol/L alone, P<0.0001). The treatment with exogenous (10(-6) mol/L) ANP and BNP reduced CYP11B2 mRNA expression (ANP, P=0.0042; BNP, P=0.0012).
CONCLUSIONS: We showed that endogenous and exogenous natriuretic peptides reduced CYP11B2 mRNA expression in cultured neonatal rat cardiocytes. This may inhibit the cardiac renin-angiotensin-aldosterone system by suppressing the gene expression of CYP11B2 and restraining cardiac hypertrophy and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591748     DOI: 10.1161/01.cir.0000057794.29667.08

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

2.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Tomoaki Nakata; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

3.  Effects of continuous infusion of low-dose human atrial natriuretic peptide (hANP) on the lungs during cardiac surgery.

Authors:  Ikuko Shibasaki; Hirotsugu Fukuda; Yasuyuki Yamada; Toshiyuki Kuwata; Takayuki Hori; Hironaga Ogawa; Go Tsuchiya
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-02-16       Impact factor: 1.520

4.  Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.

Authors:  Jessica A Chadwick; Sarah A Swager; Jeovanna Lowe; Steven S Welc; James G Tidball; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 5.  Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon.

Authors:  John C Burnett
Journal:  J Cardiol       Date:  2006-11       Impact factor: 3.159

6.  Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury.

Authors:  Yoshihisa Ogawa; Masashi Mukoyama; Hideki Yokoi; Masato Kasahara; Kiyoshi Mori; Yukiko Kato; Takashige Kuwabara; Hirotaka Imamaki; Tomoko Kawanishi; Kenichi Koga; Akira Ishii; Takeshi Tokudome; Ichiro Kishimoto; Akira Sugawara; Kazuwa Nakao
Journal:  J Am Soc Nephrol       Date:  2012-05-31       Impact factor: 10.121

7.  First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.

Authors:  Horng H Chen; Siu-Hin Wan; Seethalakshmi R Iyer; Valentina Cannone; S Jeson Sangaralingham; Joel Nuetel; John C Burnett
Journal:  Hypertension       Date:  2021-10-18       Impact factor: 10.190

8.  Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model.

Authors:  Ryuta Imaki; Shinichi Niwano; Hiroe Niwano; Daisuke Satoh; Toru Yoshida; Yoshihiko Masaki; Tohru Izumi
Journal:  Indian Pacing Electrophysiol J       Date:  2008-04-01

9.  Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

Authors:  Ramón Martos; John Baugh; Mark Ledwidge; Christina O'Loughlin; Niamh F Murphy; Carmel Conlon; Anil Patle; Seamas C Donnelly; Kenneth McDonald
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

10.  Interactive roles of NPR1 gene-dosage and salt diets on cardiac angiotensin II, aldosterone and pro-inflammatory cytokines levels in mutant mice.

Authors:  Di Zhao; Subhankar Das; Kailash N Pandey
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.